Center for Research on Rare Blood Disorders (CR-RBD)

By Burjeel Holdings
Overview
Our Team
Research Programs
Publications
Books and Guidelines
Congress Abstracts
Clinical Studies
International Collaborators
Recent News
Contact Us

The Center for Research on Rare Blood Disorders (CR-RBD) at Burjeel Medical City (Burjeel Holdings) is fully dedicated to advancing knowledge, addressing evidence gaps, and overcoming unmet needs for patients with rare blood disorders (such as thalassemia, sickle cell disease, hemophilia and other rare bleeding disorders). Our team of scholars and clinicians work together to hand-pick key research questions that reflect diagnostic and management challenges experienced throughout the entire patient journey. We also lead and participate in collaborative research networks at the regional and global level. The Center works closely with Burjeel Holdings’ Thalassemia & Sickle Cell Center to better understand patients evolving needs and offer patients opportunities to participate in innovative clinical trials.

Prof. Khaled Musallam, MD PhD

Founding Director, Center for Research on Rare Blood Disorders (CR-RBD)
Group Chief Research Officer (Burjeel Holdings)
Director, Thalassemia & Sickle Cell Center
Head, Innovative Trials Unit, Genetics and Rare Disease Center
Burjeel Medical City, Abu Dhabi, UAE
Global Research Lead
Burjeel Institute for Global Health, New York, USA
Adj. Professor, Khalifa University, Abu Dhabi, UAE
Adj. Professor, Weill Cornell Medicine, New York, USA

Our Strategy

The overarching strategy of the Center is to support better understanding of disease epidemiology and burden, identify risk factors for morbidity, mortality and diminished quality of life, and use such insights to develop novel disease-modifying or curative therapies. This is achieved through the design and conduct of a range of translational and observational studies (including real-world evidence), along with phase 1 to 4 clinical trials of novel agents.

The Center is also committed to expanding the literature with expert and systematic reviews on contemporary topics of global interest. We offer enduring research training opportunities for junior scientists and physician-scholars interested in rare blood disorders.

Our Goals

Our ultimate goal is to continually improve outcomes for patients with rare blood disorders and to cement Abu Dhabi and the United Arab Emirates’ rapidly evolving position as a global hub for research and innovation in life sciences.

Recent News

New International Thalassemia Management Guidelines Launched with Contributions from Abu Dhabi

Read moreundefined

Department of Health – Abu Dhabi to conduct clinical trials to develop thalassemia treatments

Read moreundefined

Contact Us

undefined
Ground Floor
Burjeel Medical City
28th St, Mohamed Bin Zayed City
PO Box 92510, Abu Dhabi, UAE